Hap Trading, LLC Genprex, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$1.0 - $58.8 $2,000 - $117,600	2,000 Added 11.43%	19,500 $1,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $58.0 $3,300 - $145,000	-2,500 Reduced 12.5%	17,500 $1,000
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.31 $7,552 - $13,629	5,900 Added 41.84%	20,000 $1,000
Q1 2022 May 12, 2022	SELL	$1.82 - $3.5 $1,274 - $2,450	-700 Reduced 4.73%	14,100 $5,000
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $3,267 - $7,290	2,700 Added 22.31%	14,800 $2,000
Q3 2021 Nov 10, 2021	SELL	$2.59 - $3.36 $153,328 - $198,912	-59,200 Reduced 83.03%	12,100 $4,000
Q2 2021 Aug 11, 2021	BUY	$3.11 - $4.87 $9,330 - $14,610	3,000 Added 4.39%	71,300 $18,000
Q1 2021 May 14, 2021	BUY	$3.66 - $7.67 $126,270 - $264,615	34,500 Added 102.07%	68,300 $54,000
Q4 2020 Feb 16, 2021	BUY	$3.03 - $5.51 $46,965 - $85,405	15,500 Added 84.7%	33,800 $21,000
Q3 2020 Nov 13, 2020	BUY	$2.9 - $4.29 $53,070 - $78,507	18,300 New	18,300 $11,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.